‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

‘Classical’ mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21) have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC. The aim of the current study was to evaluate whether other than the classical G719X, DEL19 and L858R mutations of EGFR con...

Descripción completa

Detalles Bibliográficos
Autores principales: Pallis, A G, Voutsina, A, Kalikaki, Ar, Souglakos, J, Briasoulis, E, Murray, S, Koutsopoulos, A, Tripaki, M, Stathopoulos, E, Mavroudis, D, Georgoulias, V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360265/
https://www.ncbi.nlm.nih.gov/pubmed/18000506
http://dx.doi.org/10.1038/sj.bjc.6604068

Ejemplares similares

Ejemplares similares